# Famitinib in Combination With Adebrelimab for the Treatment of Advanced Thyroid Cancer

> **NCT06146985** · PHASE2 · UNKNOWN · sponsor: **Ruijin Hospital** · enrollment: 67 (estimated)

## Conditions studied

- Thyroid Cancer

## Interventions

- **COMBINATION_PRODUCT:** 20 mg Famitinib & 1200 mg Adebrelimab

## Key facts

- **NCT ID:** NCT06146985
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-12-01
- **Primary completion:** 2024-11-15
- **Final completion:** 2025-05-01
- **Target enrollment:** 67 (ESTIMATED)
- **Last updated:** 2023-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06146985

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06146985, "Famitinib in Combination With Adebrelimab for the Treatment of Advanced Thyroid Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06146985. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*